ArticleOncotarget2016

Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.

Maryam Zanjirband et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.